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Abstract 
 
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) invariably 
arises from a background of chronic microbial infection and/or autoimmune disorder at diverse mucosal 
sites.  The prolonged chronic infection and/or autoimmunity generate active immune and inflammatory 
responses that provide a setting for evolution and development of autoreactive B-cells, their expansion and 
eventual malignant transformation following acquisition of genetic changes.   The immune responses also 
play a critical role in sustaining the growth and survival of the transformed cells as shown by complete 
regression of a high proportion of MALT lymphoma of the stomach, ocular adnexa and skin following anti-
microbial treatment.   B-cell receptor engagement by auto-antigen as well as T-cell help including both 
cognate interaction and bystander help via soluble ligands such as CD40L and BAFF are thought to underpin 
the immunological drive in the lymphoma development through activation of the canonical and non-
canonical  NF-B pathway respectively.  Similarly,  the three MALT lymphoma associated chromosome 
translocations, namely  t(14;18)(q32;q21)/IGH-MALT1, t(1;14)(p22;q32)/BCL10-IGH, and t(11;18)(q21;q21) 
/BIRC3 (API2)-MALT1, are also capable of activating both canonical and non-canonical NF-B pathways.  
Furthermore, TNFAIP3 (A20) inactivation by deletion and/or mutation abolishes the auto-negative feedback 
to several signalling including BCR and TLR, which connect to the canonical NF-B activation pathway.   Thus, 
there is a considerable overlap in the molecular pathways dysregulated by immunological drive and somatic 
genetic changes, strongly arguing for their oncogenic cooperation in the development of MALT lymphoma.  
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Nuclear factor (NF)-B is a family of dimeric transcription factors critical for both innate and adaptive 
immunities.  In response to stimulation of a wide range of surface receptors, NF-B orchestrates gene 
expression and governs a variety of biological processes important for the development, maturation and 
function of immune cells.  There are five NF-B subunits including RelA (p65), RelB, c-Rel, NF-B1 (p50 and 
its precursor p105) and NF-B2 (p52 and its precursor p100).  They form various hetero or homodimers, but 
are kept inactive in the cytoplasm by their inhibitor (IB, IBβ and IBε) or in its dormant precursor form. 
In response to surface receptor signalling, the quiescent NF-B dimer is activated, and permitted for nuclear 
translocation and transcriptional function.  NF-B activation is mediated via two common signalling 
pathways, namely canonical and non-canonical NF-B pathway, and this is a transient and highly regulated 
process in response to extracellular signals under a physiological condition.   Below highlights the key steps 
relevant to this review and for details on NF-B signalling please refer to other reviews [1-4].    
 
1. NF-B activation pathway  
 
Canonical NF-B pathway.  This involves IB phosphorylation by the IB kinase (IKK) complex, triggering its 
K48-linked polyubiquitination and subsequent degradation by proteasome.   As a result, NF-B dimers are 
released and their nuclear localisation signal exposed, thus enabling their nuclear translocation and 
transcriptional activities (Figure 1). 
 
Canonical NF-B pathway is activated by stimulation of several surface receptors such as B-cell receptor 
(BCR), Toll-like receptor (TLR), interleukin 1 receptor (IL1R) and tumour necrosis factor receptor (TNFR).  
These receptor stimulations initiate various signalling cascades that involve distinct adaptor molecules, but 
converge on the canonical NF-B activation pathway.  For example, BCR engagement triggers receptor 
aggregation, promoting tyrosine phosphorylation of CD79A (Igα) and CD79B (Igβ) ITAM (immunoreceptor 
tyrosine-based activation motif), and recruitment of spleen tyrosine kinase (SYK).  SYK activation then 
emanates multiple sigalling cascades that connect to the canonical NF-B, PI3K–AKT and RAS-ERK activation 
pathways [1,2].  Through the Bruton's tyrosine kinase (BTK) and protein kinase C (PKC) β signalling cascade, 
the scaffolding adaptor CARD11 (CARMA1) is recruited, undergoes conformational changes and is able to 
interact with BCL10 and promote its polymerisation and filament formation, subsequent assembly of the 
CARD11/BCL10/MALT1 (CBM) signalosome complex [5-7].  The CBM complex further recruits TNF receptor 
associated factor-6 (TRAF6), transforming growth factor  activating kinase-1 (TAK1) and TAK binding 
protein-2 (TAB 2), which activates the IKK complex and culminates the activation of canonical NF-B 
pathway [5,8,9].  Similarly, TLR (or IL1R) engagement triggers its dimerisation and conformational change in 
its Toll/IL-1R homologous (TIR) domain, which results in recruitment of MYD88, Interleukin-1 receptor-
associated kinase-4 (IRAK4) and IRAK1, forming the Myddosome complex (Figure 1). The Myddosome 
complex then recruits TRAF6, TAK1 and TAB2, subsequently leading to activation of the IKK complex and 
canonical NF-B pathway [3,4].  
 
The canonical NF-B activation pathway is also tightly modulated by several negative regulators including  
TNF inducible protein 3 (TNFAIP3, also known as A20), IB and CYLD (cylindromatosis) to ensure 
appropriate level and length of NF-B activation (Figure 1) [10,11].  IB and TNFAIP3 are the transcriptional 
targets of NF-B, and their expression following NF-B activation could serve as an auto-negative feedback.  
TNFAIP3 can inactivate a number of NF-B signalling molecules including receptor-interacting protein-1/2 
(RIP1/2), ubiquitin-conjugating enzyme 13 (Ubc13) and IKK (also known as NF-B  essential modulator, 
NEMO), thus negatively regulating the signalling of several surface receptors including BCR, TNFR, TLR and 
IL1βR [12-14].   
 
Non-canonical NF-B pathway:  This involves successive activation of the NF-B inducible kinase (NIK) and 
IKK (Figure 1).  The activated IKK phosphorylates NF-B2 (p100) and triggers its partial proteolysis, and 
this generates a functional active form p52, which is permitted, together with RelB, for nuclear translocation 
4 
 
and transcriptional function.  The signalling from CD40, B cell activating factor receptor (BAFFR), TNFRSF13B 
(also known as TACI) and lymphotoxin β receptor (LTβR) primarily activates the non-canonical NF-B 
pathway.  The non-canonical NF-B pathway is negatively regulated by TRAF3, apoptosis inhibitor-1/2 
(API1/2) and TRAF2, which control the turnover of NIK by targeting it for ubiquitin mediated degradation by 
proteasome [15].  
 
In view of the diverse signalling that trigger NF-B activation and its multiple functional roles in both innate 
and adaptive immunities, it is not surprising that NF-B dysregulation is implicated in a wide range of 
lymphomas including extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT 
lymphoma), activated B-cell like diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, 
Hodgkin’s lymphoma and multiple myeloma [16,17].  Among these, MALT lymphoma provides a unique 
model to appreciate the role of various immunological stimulations and genetic changes, and their 
oncogenic cooperation in lymphoma pathogenesis. 
 
2. MALT lymphoma is causatively linked to chronic inflammation   
 
MALT lymphoma may occur at diverse anatomic sites, but always at those that are devoid of any native 
organised lymphoid tissue.  However, such organised lymphoid tissue can be acquired following a prolonged 
chronic microbial infection or autoimmune disorder, and it has been proposed that MALT lymphoma 
originates from the marginal zone B-cells of the acquired MALT as suggested by their immunophenotype and 
preferential marginal zone localization [18].   Although not yet fully characterised, MALT lymphoma at 
several sites is associated with distinct aetiological factors.   For example, the vast majority of gastric MALT 
lymphomas develop from a background of chronic gastric Helicobacter pylori infection, while those from the 
skin and ocular adnexa, and immunoproliferative small intestine disease are variably associated with chronic 
infection of Borrelia burgdorferi [19-24], Chlamydia psittaci [25-28], and Campylobacter jejuni [29] 
respectively.  Furthermore, MALT lymphoma of the salivary gland and thyroid are commonly derived from a 
background of lymphoepithelial sialadenitis and Hashimoto thyroiditis respectively [30,31].  For detailed 
association between etiological factors and MALT lymphoma, please refer to excellent recent review [32].   
Despite association with different aetiological factors, the development of MALT lymphoma may follow a 
similar multistep process (Figure 2).  The prolonged chronic microbial infection or autoimmunity generates 
immune and inflammatory responses that maintain a population of dynamic B-cells in a microenvironment 
at an increased risk of genomic damage.  B-cells attaining certain immunological properties and/or genetic 
changes may gain growth advantage and undergo clonal expansion, eventually emerge as a transformed 
clone on rare occasions.  Presence of minor clonal B-cells in reactive conditions such as H. pylori associated 
gastritis,  lymphoepithelial sialadenitis and Hashimoto thyroiditis, and their subsequent clonal progression to 
an overt MALT lymphoma have been well described in literature [33-37].   
Apart from malignant transformation, the immune and inflammatory responses are also critical for 
sustaining the growth and survival of the transformed cells.   This is best illustrated by the findings that a 
high proportion of MALT lymphoma of the stomach, ocular adnexa and skin can be successfully treated by 
eradication of the associated microbial organisms using antibiotics [38-41].  The potential factors that 
sustain malignant B-cells are numerous.  The immune responses generate a network of B-cell helper signals, 
such as those from T-cells, dendritic cells and innate lymphoid cells, which are also potentially important for 
malignant B-cells.  In addition, the inflammatory responses likely produce further growth factors and 
cytokines, which may support malignant B-cells.  Despite numerous potential helper signals from the 
immune and inflammatory responses, the occurrence of MALT lymphoma is rather a rare event, indicating a 
highly selective process for B-cell clones that acquire certain immunological properties, such as aberrant 
responses to their microenvironment.  Although not yet fully investigated, there is evidence to suggest that 
several surface receptor signalling may underpin the immunological drive in development of MALT 
lymphoma.     
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3. Immunological drive   
 
3.1.  BCR signalling  
 
i) Biased IG gene usage in MALT lymphoma  
 
Sequence analysis of the rearranged IG genes in MALT lymphoma shows evidence of positive or negative 
selection of replacement mutations, indicating antigen mediated affinity maturation.  There is increasing 
evidence showing that there is a biased usage of certain IG genes in MALT lymphoma, particularly in those of 
the stomach, ocular adnexa and salivary gland where a relatively reasonable number of cases has been 
investigated.  In the vast majority of the related studies, particularly those of earlier investigations, the focus 
is largely on the analysis of the rearranged IG heavy chain genes.  In general, MALT lymphoma of the ocular 
adnexa and salivary glands clearly show a significantly biased usage of IGHV4-34 and IGHV1-69 respectively, 
while those of the stomach appear to show over-representation of IGHV3-7 and IGHV1-69 usage (Table 1).  
Although not yet fully characterised, the biased usage of IGHV4-34 and IGHV1-69 in MALT lymphoma are 
also in association with a biased usage of IG light chain genes (IGKV3-20) [42,43], further arguing for their 
recognition of defined antigenic determinants.  Interestingly, the biased usage of  IGHV4-34 in ocular 
adnexal MALT lymphoma is far more prevalent in those negative for Chlamydia psittaci [44].   
 
ii) Properties of immunoglobulin expressed by MALT lymphoma. 
 
Despite the causative relationship between microbial infection and MALT lymphoma at several anatomic 
sites, there is no evidence yet showing that the lymphoma derived immunoglobulin recognises microbial 
antigens [42,43,62].  Instead, there is mounting evidence indicating that at least a high proportion of 
immunoglobulins expressed by MALT lymphoma of various sites are auto-reactive as shown by analysis of 
their recombinant antibodies and/or demonstration of their high homology to a stereotypic 
complementarity determining region 3  (CDR3) sequence, such as those of rheumatoid factors (RF) (Table 2).   
 
In a large survey of lymphoma derived IG gene sequences for homology to RF associated stereotypic CDR3 
sequences, Bende and colleagues have demonstrated that a high proportion of MALT lymphoma of the 
salivary gland (41%) and stomach (18%), but not those from the lung, harbour significant homology to the 
CDR3 sequences of canonical RFs (IGHV1-69-RF, IGHV3-7-RF and WOL-RF) [42].  In vitro binding analysis of 
the recombinant antibodies from the representative MALT lymphoma associated IGHV1-69 or IGHV3-7 
rearrangements confirms their activities to the Fc portion of human IgG [42].  Moreover, strong RF activities 
are also demonstrated for recombinant antibodies from two MALT lymphomas that harbour classic RF 
IGHV1-69/IGHJ4 rearrangement, but not yet meet the criteria for a high homology to a RF CDR3 sequence, 
and additionally from a HCV-associated MALT lymphoma that harbours a novel IGHV4-59/IGHJ5 stereotypic 
rearrangement [42,63].   These findings indicate that the true frequency of MALT lymphomas that express 
BCR bearing RF activities is underestimated.     
 
The IGHV4-34 rearrangement frequently seen in ocular adnexal MALT lymphoma is also most likely 
autoreactive.  Autoantibodies encoded by IGHV4-34 rearrangement in reactive B-cells are known for their 
dependence on the unique and conserved germline FR1 hydrophobic patch (Q6W7 and A24V25Y26), which is 
critical for binding to N-acetyl-lactosamine residues, present in a wide range of surface glycoproteins [64].  
Importantly, the germline FR1 hydrophobic patch is commonly spared by somatic mutations in lymphomas 
including ocular adnexal MALT lymphoma (personal communication with Dr Richard Bende, July 2016) [65].   
Furthermore, analysis of recombinant antibodies from MALT lymphomas that harbour IGHV4-34 
rearrangement confirms their polyreactivity [43]. 
 
Apart from the above well-characterised IG gene rearrangements that encode autoantibodies, there is 
further evidence of polyreactivity of MALT lymphoma associated-BCRs encoded by other IG gene 
6 
 
rearrangements such as those involving IGHV3-23 and IGHV3-30, IGHV3-33 and IGHV3-66, as shown by 
several recombinant antibody studies [42,43,48,62].  As the number of cases investigated to date is small, 
the extent of autoreactive BCR expressed by MALT lymphoma is likely not yet fully appreciated.   
 
iii) Evidence of BCR signalling is operational in MALT lymphoma 
There are several strands of evidence indicating that the BCR expressed by MALT lymphoma cells is 
operational.  The lymphoma cells almost always express surface IgM, and possess a range of biological 
properties of reactive B-cells including ability to undergo blast transformation, plasma cell differentiation 
and even further “germinal centre reaction”, known as follicular colonisation [66,67].  While in the colonised 
follicles, MALT lymphoma cells show active proliferation and similar phenotypic changes like reactive B-cells.  
Genetically, MALT lymphoma cells frequently exhibit intraclonal  variations or ongoing mutations in their 
rearranged IG genes, which are probably the result of their follicular colonisation of reactive B-cell follicles 
[45,53,68-70].  Like normal B-cells, these phenotypic and genetic changes in MALT lymphoma cells are most 
likely the result of their responses to microenvironment milieu including stimulation through surface BCR, 
co-stimulating receptors and cytokine receptors.   It is highly likely that BCR engagement by autoantigen 
triggers a chronic and active BCR signalling, thus causes NF-B activation, consequently enhancing the 
lymphoma cell survival and proliferation.  In line with this, crosslinking surface IgM on MALT lymphoma cells 
is capable of stimulating their proliferation or enhancing their proliferative responses to mitogens [71].   
Nonetheless, BCR engagement alone is unlikely sufficient to maintain the growth and survival of MALT 
lymphoma cells in view of the evidence that a high proportion of MALT lymphoma of the stomach, ocular 
adnexa and skin show complete regression following anti-microbial treatment.   Thus, the immune and 
inflammatory responses other than direct BCR stimulation, which are eliminated following anti-microbial 
treatment, may be the major player in sustaining the survival of lymphoma cells.       
 
3.2.  T-cell help and CD40 signalling 
 
Among the many B-cell helper signals present in the microenvironment of MALT lymphoma, only T-cell help 
has been fairly investigated and this is largely based on studies of gastric MALT lymphoma.  Although gastric 
MALT lymphoma is causatively linked to chronic H. pylori infection, H. pylori antigens do not directly 
stimulate the neoplastic B-cells, but rather activate H. pylori specific tumour infiltrating T-cells and through 
them to promote the survival and proliferation of lymphoma B-cells [62,72].  This involves cognate 
interaction between B and T-cells [73-75], and also bystander T-cell help via soluble ligands and cytokines, 
such as CD40L and BAFF, thus activating the non-canonical NF-B pathway (Figure 1) [76].  In support of this, 
reactive B-cell follicles are invariably present in gastric MALT lymphoma, and these reactive components 
provide a setting for classical immunological responses that generate H. pylori specific T-cells.  An enriched 
expression of proinflammatory cytokines such as IL8 and IL1, molecules involved in B and T-cell interaction 
such as CD86, CD28 and ICOS is seen in gastric MALT lymphoma, particularly those without chromosome 
translocation [77].  In addition, in the mouse model of Helicobacter induced gastric MALT lymphoma, Th2 
cytokines such as IL4, rather than CD40 signalling, have been thought to play a critical role in the 
proliferation of lymphoma cells [78].  
 
Clearly,  the immune and inflammatory responses are critical for the evolution and emergence of aurorective 
cells, their malignant transformation and subsequent clonal expansion.  Although the survival of MALT 
lymphoma cells in a high proportion of cases is still highly dependent on such immunological drive, such an 
effect of immunological drive is likely additive or  synergistic to those conferred by acquired genetic changes 
as immunological drive alone is not sufficient for malignant transformation.         
 
4.  Genetic abnormalities 
   
The spectrum of genetic abnormalities underlying the molecular mechanisms of MALT lymphoma has not 
been explored by whole genome or whole exome sequencing, and thus remains to be fully investigated.  
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Despite this, various genetic abnormalities identified in MALT lymphoma to date have been shown 
commonly targeting the signalling pathways that regulate the NF-B activities.   These genetic abnormalities 
include chromosome translocations, somatic mutations and copy number changes, and intriguingly occur at 
remarkably variable frequencies in MALT lymphoma of different anatomic sites despite targeting the same 
or a similar molecular pathway.      
 
4.1.  t(1;14)(p22;q32)/BCL10-IGH   
 
This translocation occurs primarily in MALT lymphoma of the lung (9%) and stomach (4%) (Figure 3),  and 
juxtaposes the BCL10 gene under the regulatory control of the IG gene enhancer, leading to BCL10 over-
expression (Figure 4) [79-81].  BCL10 is an essential component of the CARD11/BCL10/MALT1 signalosome 
complex that relays the antigen receptor signalling to the canonical NF-B activation pathway (Figures 1 & 5) 
[6,82].  Over-expression of BCL10 causes its constitutive activation through oligomerisation via its N-terminal 
CARD/CARD interaction, and thus leads to enhanced NF-B activities.  Intriguingly, BCL10 protein is 
aberrantly expressed in the nuclei of lymphoma cells with t(1;14)(p22;q32)/BCL10-IGH or 
t(11;18)(q21;q21)/BIRC3 (API2)-MALT1, and also in the marginal zone B-cells of Eu-BCL10 mice [79,83-86], 
suggesting a yet unappreciated role of nuclear BCL10 in the pathogenesis of MALT lymphoma.   
 
Apart from the canonical NF-κB pathway as detailed above, there is also evidence for a role of BCL10 in the 
regulation of non-canonical  NF-κB pathway.   Bcl10 deficiency B-cells show a reduced expression of NF-B2 
(p100), and also a reduced nuclear accumulation of the non-canonical p52/RelB complex following BAFF 
stimulation [87].  In contrast, B-cells in E-BCL10 mice exhibited constitutive activation of both canonical and 
non-canonical NF-κB signalling pathways, and the activation of non-canonical pathway was thought to be 
indirect via up-regulation of BAFF expression [86].  In keeping with these findings, BAFF has been shown to 
be over-expressed in MALT lymphoma [88,89].   
 
4.2.  t(14;18)(q32;q21)/IGH-MALT1 
 
This translocation occurs mainly in MALT lymphoma of the ocular adnexa (7%) and lung (6%) (Figure 3), and 
causes MALT1 over-expression [90-92].  MALT1 contains several functional domains including an N-terminal 
death domain, three immunoglobulin-like domains and a proteolytically active caspase-like domain (Figure 
4).  Through its two N-terminal Ig-like domains, MALT1 interacts with BCL10, triggering its own 
oligomerisation and activation, thus enhances canonical NF-κB signalling (Figures 1& 5) [93,94].  This is 
supported by a strong accumulation of both MALT1 and BCL10 in the cytoplasm of the lymphoma cells 
carrying t(14;18)(q32;q21)/IGH-MALT1, a very distinct expression pattern from those of MALT lymphoma 
with t(1;14)(p22;q32)/BCL10-IGH or t(11;18)(q21;q21)/BIRC3 (API2)-MALT1  [90].   
 
Through its protease activities, MALT1 also regulates NF-B activation by specific cleavage of several NF-B 
regulators including TNFAIP3 (A20), CYLD, RelB and BCL10, thus inactivating the function of these proteins 
[95-98].  Among these, TNFAIP3, CYLD and RelB are NF-κB negative regulators and are thus particularly 
relevant in lymphoma pathogenesis [95-99].  For example, TNFAIP3 is a transcriptional target of NF-κB, 
serves as a “global” feedback regulator to attenuate NF-κB activity by inactivation of NEMO, TRAF6, and RIP1, 
thus negatively regulating several cellular signalling that activate the canonical NF-κB pathway (Figures 1& 5) 
[12,100-102].  Constitutive activation of MALT1 by translocation may abolish the above NF-B negative 
regulators, eliminating the physiological auto-negative feedback and causing relentless NF-B activation.           
 
MALT1 also plays a role in regulation of non-canonical NF-B activation pathway, and its deficiency in B-cells 
significantly reduces the BAFF-induced phosphorylation and degradation of NF-B2 (p100), thus decreases 
transcriptionally active p52 [103].  Consequently, MALT1 deficiency significantly impairs BAFF-induced cell 
survival, and interestingly this affects only marginal zone B-cell, but not follicular B-cells [103].  These 
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findings suggest that over-expression MALT1 by chromosome translocation may also lead to dysregulation of 
the non-canonical NF-B activation pathway. 
 
In addition, MALT1 can directly interact with and activate caspase-8 in a protease independent manner, and 
direct its function to activate the NF-B pathway rather than apoptosis pathway upon antigen receptor 
stimulation in T-cells [104,105].   It remains to be investigated whether this MALT1 function is also 
operational in B-cells, hence has a potential role in lymphoma pathogenesis.  
 
4.3.  t(11;18)(q21;q21)/BIRC3(API2)-MALT1   
 
This translocation occurs predominantly in MALT lymphoma of the stomach (24%),  lung (38%) (Figure 3) 
[90,91], and causes a chimeric fusion between the N-terminal API2 and the C-terminal MALT1 (Figure 4) 
[106-108].  The resulting API2-MALT1 fusion product gains novel abilities to confer oncogenic activities via 
activation of both canonical and non-canonical NF-B pathways (Figure 5).   
 
The API2-MALT1 fusion products are also capable of auto-oligomerisation through heterotypic interaction 
between the BIR1 of the API2 moiety and the C-terminal region of MALT1, thus resulting in constitutive 
activation of the canonical NF-B pathway [109,110].  Like MALT1, API2-MALT1 can also cleave TNFAIP3/A20 
and CYLD and eliminate these physiological negative feedback regulations (Figure 5) [95,111].  In addition, 
the API2-MALT1 induced NF-B activation may enhance its own expression since API2 is a transcriptional 
target of NF-B [112].  In keeping with this speculation, high levels of polyubiquitination of NEMO are seen in 
MALT lymphomas with t(11;18)(q21;q21)/API2-MALT1 and also in marginal zone B-cells of E-API2-MALT1 
mice [110,113]. 
 
The API2-MALT1 fusion product also gains ability to activate the non-canonical NF-κB pathway (Figure 5).  
The API2 moiety of the fusion product recruits NIK and places it in close proximity with the activated MALT1 
protease domain, leading to cleavage of NIK at arginine 325.  This generates a C-terminal NIK fragment that 
retains kinase activity and resists to TRAF3 dependent proteasomal degradation, and consequently causes 
constitutive signalling to activate the non-canonical NF-κB pathway [114]. 
 
Furthermore, the API2-MALT1 fusion product cleaves the tumour suppresser protein LIMA1 (LIM domain 
and actin-binding protein-1) via concerted actions of the API2 moiety and MALT1 caspase-like domain, and 
generates a novel oncogenic LIM domain-only (LMO) fragment (Figure 5) [115].  Expression of the LMO 
fragment promotes survival and proliferation of primary B-cells in vitro and tumour formation in xenograft 
model [115], albeit its molecular mechanism remains to be investigated.    
 
4.4.  TNFAIP3 (A20) inactivation  
 
TNFAIP3 deletion and/or inactivation mutation are largely seen in MALT lymphomas of the ocular adnexa, 
salivary gland and thyroid, in which the above chromosome translocations are absent or rare (Figure 3) [116-
120].    Unlike the above chromosome translocations that are specific to MALT lymphoma,  TNFAIP3/A20 
deletion and inactivating mutations are also frequently seen in a range of other lymphoma entities [119-124].  
TNFAIP3 contains an N-terminal OTU domain that possesses deubiquitinating activity, and 7 zinc finger 
domains in its C-terminus, which confers the E3 ubiquitin ligase activity (Figure 4) [10,100].  Through 
removing the K63-linked ubiquitin chain, catalysing the K48-linked polyubiquitination and also direct binding 
to the linear polyubiquitin chain of its targets, TNFAIP3 can inactivate several NF-B positive regulators 
including RIP1/2, TRAF6 and IKK (Figure 1) [12,101,102].  Thus, TNFAIP3 inactivation can potentially 
augment NF-B activation triggered by signalling from multiple surface receptors.   
 
4.5.  MYD88 mutation:   
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This occurs in ~5% of occular adnexal MALT lymphoma, and comprises novel inframe deletions as well as 
previously identified hotspot mutations such as L265P in the TIR domain, which is found frequently in several  
other B-cell lymphoma subtypes (Figures 3 & 4) [125-129].  These different mutations have been shown to 
be a gain-of-function change [125,127].   MYD88 mutants are constitutively active and capable of 
spontaneously assembling a protein complex containing IRAK1 and IRAK4, thus signalling to activate NF-κB, 
STAT3 and AP1 transcription factors  (Figure 1) [125].   
 
Somatic mutations in other NF-κB regulators:   Although this has not yet been comprehensively investigated, 
several studies show that the somatic mutations of other NF-κB regulators including CD79A, CD79B, CARD11, 
BIRC3, TRAF3 and TNFRSF11A, which are frequently seen in several B-cell lymphomas characterised by 
constitutive NF-κB activation, are rare in MALT lymphoma [126-128,130-132].  The extent of common and 
unique genetic abnormalities between MALT lymphoma and other B-cell lymphomas characterised with 
constitutive NF-κB activities remains to be investigated. 
 
4.6.  Other chromosome translocations:   
 
There are also several novel chromosome translocations including t(3;14)(p13;q32)/FOXP1-IGH [133-135], 
t(1;14)(p21;q32)/CNN3-IGH, t(5;14)(q34;q32)/ODZ2-IGH, t(9;14)(p24;q32)/JMJD2C-IGH [136] and 
t(X;14)(p11.4;q32)/GPR34-IGH [137,138], which are reported in isolated cases of MALT lymphoma.   These 
translocations are predicted to cause over-expression of the oncogene involved as these are in association 
with the IGH gene locus, thus under the transcriptional control of the IG gene enhancer.  The molecular 
mechanism underlying the oncogenic activities of these genetic events remains to be investigated.    
 
5. Oncogenic cooperation among immunological stimulation and genetic changes 
 
There is firm evidence that none of the genetic abnormalities in MALT lymphoma alone is sufficient for 
malignant transformation.  Both E-BCL10 and E-API2-MALT1 mice develop splenic marginal zone 
hyperplasia but not lymphoma [86,113], while TNFAIP3 (A20) deficiency in B-cells enhances B-cell 
proliferation with an excessive production of self-reactive autoantibodies [139].  However, stimulation of E-
API2-MALT1 mice with Freund’s complete adjuvant leads to development of splenic marginal zone 
lymphoma-like lesion [140], suggesting oncogenic cooperation between genetic abnormalities and 
immunological stimulations. 
 
As discussed above, there is a considerable overlap in the signalling pathways dysregulated by 
immunological stimulations and genetic changes (Figure 5).   For example, the receptor signalling that leads 
to canonical NF-κB pathway activation, such as BCR and TLR (toll-like receptor), and those resulting in non-
canonical NF-κB pathway activation such as BAFFR and CD40, are affected by both immunological 
stimulations and genetic changes.  These signalling pathways and their concerted actions are known to be 
critical for the development and function of marginal zone B-cells [141,142].   Such biological cooperation 
among different receptor signalling is likely operational in MALT lymphoma cells, but in a remarkably 
dysregulated manner due to constitutive activations by auto-reactive BCR and genetic changes.  For example, 
the constitutive activation of both canonical and non-canonical NF-κB pathways by chromosome 
translocation can be further augmented by chronic stimulation of surface BCR, TLR, BAFFR and CD40 [77].   
Similarly, the BCR and TLR receptor signalling conferred by microenvironment milieu can be enhanced by 
TNFAIP3 (A20) inactivation via genetic changes.  Clearly, the extent of potential oncogenic cooperation 
among immunological responses and genetic abnormalities is very much underestimated due to incomplete 
understanding of the signalling for marginal zone B-cell development as well as incomplete characterisation 
of the genetics of MALT lymphoma.  
 
6. Summary and future prospective  
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MALT lymphoma is a paradigm for illustration of oncogenic cooperation between immunological drive and 
genetic abnormalities in lymphoma genesis.  There are significant differences in the aetiology, IG gene usage 
and acquired genetic changes in MALT lymphoma of different anatomic sites despite they all share certain 
common clinicopathological features, and such variations offer excellent opportunities for discovery 
research.   Particularly, neither the immunological drive nor genetic changes have been comprehensively 
investigated in MALT lymphoma of different anatomic sites.  It is imperative to perform whole genome or 
exome sequencing analysis to characterise the somatic mutation profile of MALT lymphoma of various 
anatomic sites and dissect their molecular oncogenic mechanisms.  It is also important to comprehensively 
catalogue IG gene usage in MALT lymphoma of various anatomic sites, and characterise the properties of the 
lymphoma derived immunoglobulin.  Finally, apart from T helper cells, it is important to investigate the 
potential role of other B-cell helper signals, such as those from dendritic cells, neutrophils and innate 
lymphoid cells, in the pathogenesis of MALT lymphoma, in light of their important role in the biology of 
normal B-cells [143,144].   A comprehensive investigation of these genetic and immunological properties will 
provide rich information and insights into the molecular mechanisms and oncogenic cooperation among 
somatic  genetic abnormalities and immunological stimulations in MALT lymphoma.           
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FIGURE LEGENDS:  
Figure 1:  NF-B activation pathways and their major regulators.  The signalling from the TNFR1, TLR, IL-1R, 
and antigen receptor (BCR) activates the canonical NF-B pathway, which is characterised by activation of 
the IKK complex, phosphorylation and degradation of IB.  The signalling from CD40, BAFFR and LTβR 
activates the non-canonical NF-B pathway, which is featured by activation of NIK, proteolytic processing of 
p100 and generation of functional active p52.  The canonical NF-B pathway is negatively regulated by A20 
(TNFAIP3), a target of  NF-B, while the non-canonical pathway is negatively controlled by TRAF3.  The 
regulators that are activated by genetic changes in MALT lymphoma are highlighted by a red colour circle, 
while those that are inactivated by genetic changes are highlighted by a black colour circle.    Modified with 
permission from Du MQ, Histopathology 2011 [148].    
 
TNFR: tumour necrosis factor receptor;   TLR: toll like receptor;  IL-1R: interleukin 1 receptor;  BCR: B-cell 
receptor; TCR: T-cell receptor;  TRAF: TNF associated factor;  RIP1: receptor interacting protein 1; TAK1: 
transforming growth factor  activating kinase;  TAB: TAK binding protein;  IKK: inhibitor of NF-B kinase;  
NEMO:  NF-B essential modulator;  IB: inhibitor of NF-B;  BAFFR: B cell activating factor receptor;  LTR: 
lymphotoxin  receptor;  NIK: NF-B inducing kinase. K63Ub: K63 linked ubiquitin chain;  K48Ub: K48 linked 
ubiquitin chain.  
 
Figure 2:  Multistage development of MALT lymphoma. 
 
Figure 3:  Frequencies of genetic abnormalities in MALT lymphoma of different sites.  The data are based on 
our previous studies [79,90,116,119,145-147].  
 
Figure 4:  Key features of MALT lymphoma associated oncogenes or tumour suppresser genes. 
 
T(1;14)(p22;q32)/BCL10-IGH and t(14;18)(q32;q21)/IGH-MALT1 cause over-expression of BCL10 and MALT1 
respectively, while t(11;18)(q21;q21)/BIRC3(API2)-MALT1 fuses the N-terminal API2 to the C-terminal MALT1 
and generates a chimeric fusion product.  Various breakpoints in API2 and MALT1 and their frequencies are 
indicated.  TNFAIP3 (A20) is commonly inactivated by deleterious mutations and deletion.   Modified with 
permission from [127,148]. 
 
Figure 5:  The proposed model of molecular pathogenesis of gastric MALT lymphoma with and without 
chromosome translocation.  
 
The oncogentic products of t(1;14)(p22;q32)/BCL10-IGH, t(14;18)(q32;21)/IGH-MALT1 and 
t(11;18)(q21;q21)/API2-MALT1 activate the canonical NF-B pathway.  They may further augment their 
mediated NF-B activation by enhancing expression of surface receptors TLR6 and CCR2, as well as 
proteolytic cleavage of the negative inhibitor TNFAIP3/A20.  In addition, the API2-MALT1 fusion product 
gains ability to cleave NIK and generate a stable NIK C-terminal fragment, capable of activating the non-
canonical NF-B pathway, and also to cleave LIMA1 and generate a LIM domain-only (LMO) fragment, 
conferring oncogenic properties.  Over-expression of BCL10 or MALT1 may also indirectly enhance non-
canonical NF-B signalling via BAFFR.  These genetic changes may potentially cooperate with the signalling 
from BCR, BAFFR and CD40, together causing constitutive activation of both canonical and non-canonical NF-
B pathways. 
 
The growth of translocation negative MALT lymphoma is largely driven by H. pylori generated immune 
responses including signalling from CD40 and CD86 through bystander T-cell helps, and direct triggering of 
TLR and BCR by H. pylori associated lipopolysaccharides and autoantigen respectively.   This explains that 
most of translocation negative gastric MALT lymphomas are responsive to H. pylori eradication.  Reproduced 
with permission from [148,149].    
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TLR: toll like receptor;   BCR: B-cell receptor; MAPK: MAP kinase; IB: inhibitor of NF-B;  BAFFR: B cell 
activating factor receptor;  K48Ub: K48 linked ubiquitin chain.  NIK: NF-B inducible kinase;  LIMA1: LIM 
domain and actin-binding protein 1.  
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Table 1:  Examples of biased IG gene usage in MALT lymphoma of different anatomic sites.  
 
Sites of MALT 
lymphoma 
Aetiology Biased IG gene usage#  References 
Stomach  
Helicobacter 
pylori  
IGHV3-7 
IGHV1-69 
IGHV1-2 (?) 
IGHV3-23 (?) 
[42,45-49] 
Ocular adnexa 
Chlamydia 
psittaci 
IGHV4-34/IGKV3-20* (~12%) 
IGHV3-7 (?) 
IGHV3-23 (?) 
IGHV3-30 (?) 
 
[44,50-54] 
Salivary glands 
lymphoepithelial 
sialadenitis 
IGHV1-69/IGKV3-20 (~50%)  [42,55,56] 
Thyroid 
Hashimoto 
thyroiditis 
IGHV3-30 (?) 
 
[57] 
Skin  
Borrelia 
burgdorferi 
IGHV3-30 (?) 
IGHV1-69 (?) 
[58-60] 
Lung 
Achromobacter 
xylosoxidans 
IGHV4-34 (?) [61] 
 
#where a IGHV member might be biased used, but not yet investigated extensively, is indicated by a 
question mark;     
*frequently in Chlamydia psittaci negative cases.    
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Table 2: Properties of IG gene rearrangements and their encoded BCR in MALT lymphoma. 
   
IG genes bias-used in 
MALT lymphoma 
Known genetic features of IG 
rearrangement 
Known IG properties References 
IGHV1-69 
 short CDR3 sequence frequently with 
high homology to those of rheumatoid 
factor; 
 variable mutations in IGHV with few 
intraclonal variations; 
rheumatoid factors, 
self-polyreactive 
 
[42,48,54,56] 
IGHV3-7  
 CDR3 sequence frequently with high 
homology to those of rheumatoid 
factor; 
rheumatoid factors, 
self-polyreactive 
 
[42,48,54] 
 
IGHV3-23/IGKV3-20        n/a self-polyreactive [43] 
IGHV3-30 /IGKV1-33        n/a self-polyreactive [43] 
IGHV4-34/ IGKV3-20* 
 Contains unique and conserved FR1 
motif (Q6W7 and A24V25Y26)  
Binding to N-acetyl-
lactosamine 
residues;  
polyreactive 
[43,64,65] 
 
n/a:  not available yet 
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